408, 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – July 2022
EMA July 19 - Trastuzumab deruxtecan – BC HER2. [...]
1807, 2022
Monthly focus on regulatory status of new targeted therapies in oncology – June 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new [...]
1407, 2022
Monthly focus on regulatory status of new targeted therapies in oncology – June 2022
EMA April 1. Abemaciclib – BC HR+/HER2-. EMA has approved the dual inhibitor of (CDK) [...]
2005, 2022
Monthly focus on regulatory status of new targeted therapies in oncology – April 2022
EMA April 1. Abemaciclib - BC HR+/HER2-. EMA has approved [...]
1204, 2022
Monthly focus on regulatory status of new targeted therapies in oncology- March 2022
CHMP March 24 – pembrolizumab – CRC/EC/BTC/SBA/GC MSI-H and CC [...]
1204, 2022
ALK rearrangements: a biomarker at the forefront of NSCLC treatment
On January 28, the European Commission approved lorlatinib as monotherapy [...]
1703, 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology February 2022
EMA February 18 - tepotinib - NSCLC METex14: EMA has [...]
2302, 2022
Monthly focus on regulatory status of new targeted therapies in oncology- January 2022
EMA January 9 - sotorasib-NSCLC KRAS G12C: the European Commission [...]